Neonatal diabetes mellitus due to a rare mutation in KCNJ11 gene by Kumar, Sunil & Thakur, Anuj
Vol 5 | Issue 11 | November 2018 Indian J Child Health 703
Case Report
Neonatal diabetes mellitus due to a rare mutation in KCNJ11 gene
Sunil Kumar1, Anuj Thakur2
From 1Senior Resident, Department of Pediatrics, Kalpana Chawla Government Medical College, 2Consultant Pediatrician, Department of 
Neonatology, Thakur Hospital, Karnal, Haryana, India
Correspondence to: Dr. Sunil Kumar, Department of Pediatrics, Kalpana Chawla Government Medical College, H. No. 1420, Sector 9, 
Karnal, Haryana, India. E-mail: drsunilx@yahoo.com
Received - 07 October 2018 Initial Review - 03 November 2018 Accepted - 19 November 2018
Neonatal diabetes mellitus (NDM) is defined as insulin-requiring persistent hyperglycemia occurring in the first 6 months of life [1]. It is categorized 
into permanent neonatal diabetes and transient neonatal 
diabetes [2]. Heterozygous activating mutations, in the 
KCNJ11 and ABCC8 genes, which encode the Kir6.2 and 
sulfonylurea receptor 1 (SUR1) subunits of the ATP-sensitive 
potassium (KATP) channels that control insulin secretion are the 
most common and a rarer cause of permanent neonatal diabetes, 
respectively [3]. It is vital to recognize KATP channel mutation 
as most of these patients do not require insulin injections and 
achieve better glycemic control with sulfonylureas as in the 
current case. We describe one such case of NDM due to a rare 
KCNJ11 mutation.
CASE REPORT
This male patient was born of a non-consanguineous marriage 
without any family history of diabetes or gestational diabetes 
mellitus in the mother. The patient was born by normal vaginal 
delivery, weighing 3.5 kg at birth with no history of birth asphyxia. 
There was a history of two abortions in the mother. The child was 
being fed on cow milk with 2:1 dilution. At the age of 1.5 months, 
the patient was presented to us with the complaints of cough and 
cold for 7 days, fever for 2 days, breathing difficulty for 2 days, 
and reduced feed acceptance for 1 day. Fever was high grade, not 
responding to antipyretics, not associated with vomiting, diarrhea, 
jaundice, with no ear discharge, or crying during micturition. 
There was no history of cyanosis, feeding diaphoresis, and suck-
rest-suck cycle.
When the patient was brought to the hospital, he was febrile 
(39°C), had tachycardia (210 per min), fast and deep breathing 
(86/min) associated with chest retraction and grunting sound while 
breathing, abdominal distension, and opisthotonic posturing. 
SpO2 was 60% at admission and increased to 76% with oxygen. 
Liver and spleen were palpable 2 and 3 cm below costal margin, 
respectively.
The patient had severe metabolic acidosis with pH of 6.9 
with blood sugar >600 mg/dl, hemoglobin of 11.8 g/dl, total 
leukocyte count 8300/mm3, and C-reactive protein (CRP) was 
23.6 mg/dl. The patient was ventilated for 2 days and managed 
as diabetic ketoacidosis (DKA) with fluids and IV insulin drip. 
Anticonvulsant (levetiracetam) was given in view of convulsions 
and antibiotics (cefotaxime) were given in view of fever and 
high CRP. Blood culture was sterile. Treatment was started with 
an intravenous infusion of regular insulin (0.05 U/kg/h); as the 
condition stabilized, the patient was shifted to subcutaneous 
insulin after 4 days (Humalog mix sliding scale, 6 hourly 
monitoring of sugars with dose according to blood sugars).
As NDM is a strong possibility in any child younger than 
6 months with persistent hyperglycemia, genetic studies were sent 
which revealed a heterozygous missense variation in exon 1 of the 
heterozygous missense variation in exon 1 of the KCNJ11 gene 
(chr11:17409037C>T; depth: 10×) that results in the amino acid 
substitution of histidine for arginine at codon 201 (p.Arg201His; 
ENST00000339994).
At the age of 3.5 months, the patient developed an episode 
of fever which precipitated DKA. The patient had to be put on 
intravenous insulin and was ventilated for 3 days. As the condition 
stabilized, the patient was shifted to subcutaneous insulin.
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After stabilization, the patient was gradually shifted from 
insulin to oral sulfonylureas (glibenclamide) as this variant of 
NDM is responsive to sulfonylureas which being an oral drug is 
a better treatment option. Glibenclamide was started at a dose of 
0.1 mg/kg/dose and was gradually increased to 0.8 mg/kg/day, and 
insulin was gradually reduced accordingly. Blood sugar remained 
stabilized on this dose. The patient showed normal growth and 
development on follow-up. Electroencephalography was found to 
be normal at the age of 5 months.
DISCUSSION
NDM is a rare disease with estimated incidence of 
1:300,000–400,000 newborns, although incidence up to 1:89,000 
has been reported in some European countries [1,3]. NDM can 
either be transient NDM (TNDM) or permanent NDM (PNDM). 
TNDM, more common of the two (50%–60% of all NDM cases) 
requires initial insulin treatment but resolves spontaneously by 
a median of 12 weeks of age, only to relapse years later. On the 
other hand, PNDM requires continuous and lifelong treatment 
without any period of remission. NDM is a monogenic form of 
diabetes, with abnormal pancreatic islet development, decreased 
B-cell mass, or B-cell dysfunction causing insulin deficiency 
and should be differentiated from autoimmune diabetes which is 
extremely rare before 6 months, [4].
Approximately, a dozen genes involved in pancreatic 
development, B-cell apoptosis, or dysfunction are known to 
cause NDM. The most common cause of PNDM are mutations 
in the KCNJ11 gene, which encodes the KATP channel subunits 
KIR6.2 (ATP-sensitive inward rectifier potassium channel) and 
ABCC8 genes which encode SUR1, [4]. Mutations in genes 
that encode glucokinase, insulin promoter factor 1, pancreas 
transcription factor 1α, forkhead box P3 protein, or eukaryotic 
translation initiation factor 2-alpha kinase 3 are less frequent 
causes of PNDM [5]. The KATP channel is a heterotetrameric 
complex comprising 4 SUR1 and pore-forming KIR6.2 subunits; 
maintenance of the 1:1 ratio of SUR1:KIR6.2 is essential to both 
the assembly and function of KATP [5,6]. In normal pancreatic 
B-cells, glucose metabolism results in an increased production of 
intracellular ATP, which binds to the KIR6.2 subunit, causing the 
potassium channel to close and inhibiting potassium efflux; this 
subsequently results in cell membrane depolarization, triggering 
an influx of calcium, and initiating insulin secretion.
Mutations of the KCNJ11 gene compromise the sensitivity 
of inhibitory ATP by the KIR6.2 subunit, causing permanent 
opening of the potassium channel and preventing cell 
depolarization and insulin secretion [6]. Similarly, activating 
mutations of the ABCC8 gene decrease the channel closure and 
compromise insulin release [5]. Both KCNJ11 gene and ABCC8 
gene mutations cause insulin deficiency and clinical presentation 
is same in both. Oral sulfonylurea agents are highly effective in 
patients with KCNJ11 gene and ABCC8 gene mutations, providing 
better glycemic control than insulin [7,8]. Sulfonylureas bind to 
the SUR2 subunit of KATP channel and close the channel in an 
ATP-independent manner causing membrane depolarization and 
insulin secretion [9]. Developmental delay, epilepsy, and neonatal 
diabetes (DEND) is a less common but severe variant of PNDM 
secondary to KATP channel mutations that are associated with 
neurological features. This is believed to be the result of mutated 
KATP channels in the brain since both the KCNJ11 gene and 
ABCC8 gene are expressed in neuronal tissue. Milder form with 
less severe developmental delay and without generalized epilepsy, 
known as intermediate DEND (iDEND), is more common [7,10].
In any case, presenting with persistent hyperglycemia 
<6 months, NDM is a strong possibility and genetic screening 
must be done not only for diagnostic purpose but also it is 
important for case management (sulfonylureas sensitivity) and 
genetic counseling. Mutation found in the current case has not 
been reported from Indian population but similar mutation with 
different amino acid substitution, affecting the same codon 
(Arg201Cys), has been reported in the literature [11,12]. The 
Arg201His variant has not been reported in the genetic database 
1000 genomes and ExAC.
The patient with NDM requires regular monitoring for blood 
sugar levels and long-term complication of diabetes with regular 
screening for nephropathy and retinopathy [13]. While the course 
and severity of the disease varies greatly according to the genetic 
variant, the patient can have a good quality of life and intellectual 
development with proper care [14].
CONCLUSION
Genetic testing must be done in all cases of persistent 
hyperglycemia. The majority of patients with KATP channel mutation 
responds successfully to oral sulfonylureas, which in comparison 
to injectable insulin, drastically reduces the complexity of diabetes 
management and improves the quality of life of the patient.
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